Vimta Labs (VIMTALABS)

FairStock Score: 33/100 — RISKY

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Near-zero debt (D/E 0.02) provides balance sheet safety.
• High return ratios: ROE of 22.10% and ROCE of 25.22%.
• Piotroski F-Score of 7/9 suggests sound operational health.
• Latest quarter profitable with sales ₹99 Cr and net profit ₹18 Cr; full-year growth positive at 9.69% sales / 6.91% profit.
• Specialised healthcare research, analytics & technology positioning.

Concerns

• Rich valuation: P/E of 26.60, P/B of 6.17, and PEG of 3.20 leave little margin of safety.
• Profit growth of only 6.91% is too slow to justify a 26.6 times earnings multiple.
• Shareholder income is negligible with dividend yield of 0.22%; FairStock Score of 25/100 flags risk.
• Price has fallen 47.6% from the 52-week high, indicating possible de-rating; promoter holding at 35.90% is moderate.

AI Analysis

Vimta Labs strikes me as a good, not great, business that is currently priced as if it were a great one. The financial health is excellent: debt/equity of 0.02, ROE at 22.10%, ROCE at 25.22%, and a Piotroski F-Score of 7/9. That tells me the company generates solid returns without leverage, and its operating fundamentals have been sound. It appears to have some moat in healthcare research, analytics and technology, though the numbers alone don't quantify the durability of that moat. Promoter holding of 35.90% is adequate but not commanding. But I buy businesses at a price that gives margin of safety, and here the price is troubling. At ₹472.65, the market cap is ₹2,018 Cr, which translates into a P/E of 26.60 and P/B of 6.17. Book value is only ₹76.61, so most of what I pay is faith in future growth. Yet growth is hardly explosive: sales rose 9.69% and profit rose 6.91%. The PEG ratio of 3.20 makes the valuation look even less attractive. The latest quarter shows sales ₹99 Cr and net profit ₹18 Cr, but a single quarter does not justify a 26 times multiple. Dividend yield of 0.22% means I get no income while waiting, and the FairStock Score of 25/100 flags this as risky. I would not call this a terrible business—far from it. The balance sheet is clean and returns are high. But at this price, I am not being compensated for the risk. I would rather wait for a lower price or clearer evidence of accelerating growth. In investing, it is not enough to buy a good company; you must buy it at a good price. Vimta fails my margin-of-safety test today.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer